Table 2 Baseline characteristics of the patients in different risk groups
Characteristics | TCGA-LUAD cohort | GEO-LUAD cohort | ||||
|---|---|---|---|---|---|---|
High risk | Low risk | P value | High risk | Low risk | P value | |
Gender(%) | Â | Â | 0.09 | Â | Â | 0.25 |
 Female | 71 (46.4%) | 88 (57.1%) |  | 112 (58.9%) | 103 (53.9%) |  |
 Male | 82 (53.6%) | 66 (42.9%) |  | 78 (41.1%) | 88 (46.1%) |  |
Age (%) | Â | Â | 0.17 | Â | Â | 0.99 |
  < 65y | 74 (48.4%) | 60 (39.0%) |  | 52 (27.4%) | 52 (27.2%) |  |
  ≥ 65y | 79 (51.6%) | 94 (61.0%) |  | 138 (72.6%) | 139 (72.8) |  |
TNM stage | Â | Â | 0.03 | Â | Â | 0.01 |
 I-II | 112 (73.2%) | 120 (77.9%) |  | 152 (80.0%) | 159 (83.2%) |  |
 III-IV | 41 (26.8) | 34 (22.1%) |  | 38 (20.0%) | 32 (16.7%) |  |
TP53 |  |  | NA |  |  | < 0.001 |
 Wide type | – | – |  | 132 (69.5%) | 155 (81.1%) |  |
 Mutant type | – | – |  | 58 (30.5%) | 36 (18.8%) |  |